Generic Name: decitabine/cedazuridine

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Chemotherapy Medications

Company: Taiho

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Inqovi is a combination of two oral chemotherapy drugs, decitabine and cedazuridine, used for the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.

General Info

Inqovi combines decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a DNA methylation inhibitor. The two drugs affect processes involved in cell proliferation and may restore normal cell growth. Studies showed that about half of people who needed blood transfusions for myelodysplastic syndromes no longer did so after using Inqovi. The combination pill produces drug levels similar to those of IV infusions. Inqovi was first approved in July 2020.


Dosing Info:

Inqovi is a tablet taken once daily for five consecutive days in each monthly cycle.

Side Effects

Common adverse reactions include fatigue, mouth sores, muscle and joint pain, headache, nausea, diarrhea, constipation, decreased appetite, rash, dizziness, edema (swelling), cough, shortness of breath, pneumonia and elevated liver enzymes. Mylotarg can cause depletion of hemoglobin (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and bleeding. It can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: July 8, 2020